Berlin - Delayed Quote EUR

CytomX Therapeutics Inc (6C1.BE)

0.7215

+0.0700

+(10.74%)

At close: May 2 at 9:48:25 PM GMT+2

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

Novel engineering approach to developing an mRNA-encoded masked IL-12 therapeutic demonstrates potent anti-tumor activity with significantly enhanced tolerabilitySOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced new preclinical data in collaboration with Moderna on an mRNA encoded masked IL-12 molecule. The data will be presented at the American Association

GlobeNewswire 4 days ago

CTMX
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.

Zacks 7 days ago

CTMX
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.

Zacks 22 days ago

VLA.PA

CTMX

ANIP
SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

The EMA pauses all clinical studies of Sarepta and Roche's Elevidys following the reported death of a treated patient

Zacks 28 days ago

SRPT

ROG.SW

CTMX
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.

Zacks 29 days ago

BMRN

CTMX
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda

The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.

Zacks last month

MRK

CTMX
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection

The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.

Zacks last month

CTMX
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.

Zacks last month

SNY

CTMX
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.

Zacks last month

SNY

CTMX
Elevation Oncology Plunges 42% on Ending Development of Lead Drug

ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.

Zacks last month

ELEV

CTMX
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.

Zacks last month

AKBA

CTMX
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.

Zacks last month

ALLO

CTMX
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks last month

CTMX
CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations

CytomX Therapeutics ( NASDAQ:CTMX ) Full Year 2024 Results Key Financial Results Revenue: US$138.1m (up 36% from FY...

Simply Wall St. last month

CTMX
CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now

We recently compiled a list of the 10 Cheap Growth Stocks to Buy Now. In this article, we are going to take a look at where CytomX Therapeutics, Inc. (NASDAQ:CTMX) stands against the other cheap growth stocks. Growth stocks—those of companies expected to grow at an above-average rate compared to other firms—have historically exhibited cyclical performance […]

Insider Monkey last month

CTMX
Q4 2024 CytomX Therapeutics Inc Earnings Call

Q4 2024 CytomX Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

CTMX
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

Discover how CytomX Therapeutics Inc (CTMX) is navigating financial challenges while advancing its innovative pipeline in the latest earnings call.

GuruFocus.com last month

CTMX
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 210% and 89.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CTMX
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY® Interferon-alpha 2b) Phase 1a translational data in advanced melanoma expected in 2H 2025 - - Maintained financial strength with cash runway into Q2 2026 - - Company to host conference call today at 2 p.m. PST / 5 p.m. EST - SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Cy

GlobeNewswire last month

CTMX
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.co

GlobeNewswire last month

CTMX

Performance Overview

Return	6C1.BE	S&P 500 (^GSPC)
YTD	-30.22%	-3.31%
1-Year	-81.88%	+12.29%
3-Year	-58.26%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CytomX Therapeutics Inc (6C1.BE)

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda

GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations

CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now

Q4 2024 CytomX Therapeutics Inc Earnings Call

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Performance Overview